Chemomab Therapeutics Ltd.: Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab Therapeutics (Nasdaq: CMMB) and Scipher Medicine (Nasdaq-bound) announced a definitive merger to combine in a stock deal, with the combined company to trade on Nasdaq as Scipher Medicine Corporation under ticker SCIP. The focus is advancing nebokitug, an anti-CCL24 antibody, into a Phase 2 RA trial using Scipher’s PrismRA test. A $30M private placement supports operations into H2 2028; Phase 2 readout expected H1 2028. Valuation cited at $150M pre-merger.
How this was made
The 30-second read
Why it matters
The merger combines a clinical-stage asset (nebokitug) with a precision-medicine platform and revenue-generating diagnostics/partnership capabilities, funded by a new approximately $30M financing and expected to close in Q4 2026.
Market read
Traders can frame the event as a definitive biotech M&A catalyst with a stated cash runway into H2 2028 and a major clinical inflection point in H1 2028.
What to watch
Key missing details for pricing include the exchange ratio, CVR payout structure specifics, and any regulatory or trial-design risks beyond the stated 12-week FDA endpoints.
Background
Chemomab and Scipher announced a definitive merger to advance nebokitug, an anti-CCL24 antibody, using Scipher’s AI Network Medicine and PrismRA test for RA patient selection.
Ticker impact
Chemomab entered a definitive merger agreement with Scipher, with Chemomab equity holders expected to own about 32% of the combined company.
Likely volatility around deal milestones (S-4, shareholder votes, closing conditions), with direction dependent on financing and regulatory/approval progress.
The article discloses a definitive merger, expected close timing, and contingent value rights, which typically drive trading but without providing deal price or collar details here.
Market effects
Highlights continued investor appetite for AI-enabled precision medicine platforms and immunology-targeted antibody development.
Israel-US biotech collaboration underscores cross-border capital formation and development pipelines.
Nebokitug Phase 2 timeline and AI patient-selection approach may influence competitive positioning in RA precision medicine.
Counterpoint
The Phase 2 readout is not until H1 2028, so near-term trading may be dominated by merger mechanics rather than clinical fundamentals.
Key entities
- companyChemomab Therapeutics
Nasdaq-listed company (CMMB) developing nebokitug and entering a definitive merger with Scipher.
- companyScipher Medicine Corporation
Precision medicine company providing AI Network Medicine and PrismRA test, merging with Chemomab.
- assetnebokitug
First-in-class anti-CCL24 antibody planned for a Phase 2 rheumatoid arthritis trial with topline readout expected in H1 2028.
- diagnosticPrismRA
CMS-approved test used to predict RA treatment response and guide patient enrollment in the proposed Phase 2 design.
